T1	PROC 19 81	Estudio de fase 2, multicéntrico, aleatorizado, en doble ciego
T2	PROC 108 154	), controlado con placebo, de grupos paralelos
T3	PROC 181 212	evaluar la eficacia y seguridad
T4	CHEM 216 222	TF0023
T5	PROC 232 239	placebo
#1	AnnotatorNotes T5	C0032042; Placebos; Therapeutic or Preventive Procedure
T6	PROC 246 257	tratamiento
#2	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T7	DISO 264 272	COVID-19
#3	AnnotatorNotes T7	C5203670; COVID19 (disease); Disease or Syndrome
T8	LIVB 276 283	adultos
#4	AnnotatorNotes T8	C0001675; Adult; Age Group
T9	Age 276 283	adultos
T10	PROC 284 298	hospitalizados
#5	AnnotatorNotes T10	C0019993; Hospitalization; Health Care Activity
T11	PROC 316 333	Estudio de fase 2
T12	PROC 339 370	evaluar la eficacia y seguridad
T13	CHEM 374 380	TF0023
T14	PROC 390 397	placebo
#6	AnnotatorNotes T14	C0032042; Placebos; Therapeutic or Preventive Procedure
T15	PROC 404 415	tratamiento
#7	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	DISO 422 430	COVID-19
#8	AnnotatorNotes T16	C5203670; COVID19 (disease); Disease or Syndrome
T17	LIVB 434 441	adultos
#9	AnnotatorNotes T17	C0001675; Adult; Age Group
T18	Age 434 441	adultos
T19	PROC 442 456	hospitalizados
#10	AnnotatorNotes T19	C0019993; Hospitalization; Health Care Activity
T20	DISO 470 492	Infección por COVID-19
#11	AnnotatorNotes T20	C5203670; COVID19 (disease); Disease or Syndrome
T21	PROC 520 533	Hospitalizado
#12	AnnotatorNotes T21	C0019993; Hospitalization; Health Care Activity
T22	DISO 538 569	síntomas pulmonares de COVID-19
T23	LIVB 583 591	paciente
#13	AnnotatorNotes T23	C0030705; Patients; Patient or Disabled Group
T24	LIVB 598 617	representante legal
T25	PROC 629 653	consentimiento informado
#14	AnnotatorNotes T25	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T26	PROC 678 691	procedimiento
T27	PROC 729 743	procedimientos
T28	LIVB 770 775	Varón
T29	LIVB 778 783	mujer
#15	AnnotatorNotes T29	C0043210; Woman; Population Group | C0242665; wife; Family Group
T30	Neg_cue 784 786	no
T31	PHYS 787 797	embarazada
#16	AnnotatorNotes T31	C0032961; Pregnancy; Organism Function
T32	Negated 787 797	embarazada
T33	LIVB 799 805	adulto
#17	AnnotatorNotes T33	C0001675; Adult; Age Group
T34	Age 799 805	adulto
T35	Age 806 816	>/=18 años
T36	DISO 868 944	infección por el coronavirus del síndrome respiratorio agudo grave de tipo 2
T37	LIVB 946 956	SARS-CoV-2
#18	AnnotatorNotes T37	C5203676; SARS-CoV-2; Virus
T38	PROC 997 1032	reacción en cadena de la polimerasa
#19	AnnotatorNotes T38	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique
T39	PROC 1034 1059	polymerase chain reaction
T40	PROC 1061 1064	PCR
#20	AnnotatorNotes T40	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique | C0201657; C-reactive protein measurement; Laboratory Procedure
T41	Neg_cue 1110 1112	no
T42	PROC 1129 1138	serología
#21	AnnotatorNotes T42	C0036743; Serologic tests; Laboratory Procedure
T43	Negated 1129 1138	serología
T44	DISO 1172 1181	trastorno
#22	AnnotatorNotes T44	C0012634; Disease; Disease or Syndrome
T45	DISO 1227 1244	neuropsiquiátrico
T46	LIVB 1331 1339	paciente
#23	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	LIVB 1460 1472	investigador
#24	AnnotatorNotes T47	C0035173; Research Personnel; Professional or Occupational Group
T48	PROC 1489 1527	oxigenación por membrana extracorpórea
#25	AnnotatorNotes T48	C0015357; Extracorporeal Membrane Oxygenation; Therapeutic or Preventive Procedure
T49	PROC 1564 1568	alta
#26	AnnotatorNotes T49	C0030685; Patient Discharge; Health Care Activity
T50	PROC 1584 1608	traslado a otro hospital
T51	Neg_cue 1609 1611	no
T52	Negated 1612 1638	participante en el estudio
T53	LIVB 1612 1624	participante
